On Tuesday, 30 May 2017, Knowledge Ecology International delivered the following intervention on Preparation for the third High-Level Meeting of the General Assembly on the Prevention and Control of Noncommunicable Diseases, to be held in 2018. The statement was delivered by Thiru Balasubramaniam.
On Monday, 29 May 2017, Knowledge Ecology International delivered the following intervention on the Global vaccine action plan. The statement was delivered by James Love.
On Wednesday, 24 May 2017, Knowledge Ecology International delivered the following intervention on antimicrobial resistance. This statement was read by Andrew Goldman.
KEI would like to call attention to a proposal introduced in the United States Congress, as Senate Bill 771, sponsored by 16 US Senators, and HR 1776, which has 14 sponsors in the House of Representatives.
SEC. 409K of the bill is titled, “PRIZE FUND FOR NEW AND MORE EFFECTIVE TREATMENTS OF BACTERIAL INFECTIONS.”
>> IFLA: Thank you again Mr. Chair for allowing IFLA to take the floor. IFLA supports initiatives to support and make available cumulative knowledge and cultural heritage and recognize the role of libraries and archives in that respect. We further… Continue Reading →
Today KEI attended the annual listening session at DHHS, when speakers are alotted no more than 1.5 minutes to speak on a specific agenda item, with no more than two agenda items per speaker. Our brief comments were focused on advancing the delinkage approach in the contexts of the GSPOA, CEWG, and cancer.
On May 3, 2017, 29 civil society organizations and 33 health professionals, activists, and economists — including Nobel Prize laureate Joseph Stiglitz — asked delegates to the World Health Assembly (WHA) to support a feasibility study on the progressive delinkage of the costs of research and development from the price of cancer medicines. The groups and experts sent a letter to the delegates.
Today, KEI received a letter from the U.S. Army dated April 21, 2017, signed by Barry M. Datlof, in which the Army largely rejected concerns raised in comments submitted by KEI and various other public interest groups related to the proposed grant of an exclusive license to the French drug company Sanofi on a U.S. Army-invented vaccine for Zika virus. Continue Reading →
On March 10, 2017, KEI filed our 3rd set of comments with the U.S. Army Medical Research and Material Command (USAMRMC) on their proposed grant of an exclusive license on Zika virus vaccine patents to the French pharmaceutical company Sanofi.
December 21, 2016 — KEI has filed comments with the U.S. Army Medical Research and Materiel Command (USAMRMC) on the proposed grant of an exclusive license to Sanofi on patents on a vaccine for Zika Virus.